News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Vivaldi Coelho Rogerio
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 12,169 shares
@ $0
Disposed/sold 35,382 options to buy
@ $0.75, valued at
$26.5k
|
|
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/09/2023 |
4
| Vivaldi Coelho Rogerio (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Bought 5,000 shares
@ $22.06, valued at
$110.3k
|
|
| 03/01/2023 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 460,000 options to buy
@ $1.09, valued at
$501.4k
|
|
| 06/21/2022 |
4
| Vivaldi Coelho Rogerio (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Granted 8,750 options to buy
@ $18.29, valued at
$160k
|
|
| 02/22/2022 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 230,000 options to buy
@ $1.48, valued at
$340.4k
|
|
| 01/10/2022 |
4
| Vivaldi Coelho Rogerio (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $28.31, valued at
$707.8k
|
|
| 01/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/05/2021 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 50,000 shares
@ $0 |
|
| 02/16/2021 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $39.81, valued at
$8M
|
|
| 12/10/2020 |
4
| Vivaldi Coelho Rogerio (President and CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Converted 22,222 shares
@ $0
Converted 22,222 convertible preferred
@ $0 |
|
| 03/08/2018 |
4
| Vivaldi Coelho Rogerio (EVP, Chief Global Therapeutics) has filed a Form 4 on Bioverativ Inc.|
Txns:
| Disposed/sold 5,758 shares
@ $0
Disposed/sold 14,230 restricted stock units
@ $0
Disposed/sold 42,727 restricted stock units
@ $0
Disposed/sold 113,230 options to buy
@ $44.51, valued at
$5M
Disposed/sold 56,615 options to buy
@ $44.51, valued at
$2.5M
|
|
| 02/15/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2018 |
4
| Vivaldi Coelho Rogerio (EVP, Chief Global Therapeutics) has filed a Form 4 on Bioverativ Inc.|
Txns:
| Granted 42,727 restricted stock units
@ $0 |
|
| 02/16/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/19/2016 |
4
| Vivaldi Coelho Rogerio (Chief Commercial Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 5,600 shares
@ $52.96, valued at
$296.6k
Sold 1,400 shares
@ $53.32, valued at
$74.6k
Exercised 1,000 options to buy
@ $3.45, valued at
$3.5k
Exercised 5,000 options to buy
@ $7.5, valued at
$37.5k
|
|
| 04/22/2016 |
4
| Vivaldi Coelho Rogerio (Chief Commercial Officer) has filed a Form 4 on Spark Therapeutics, Inc.|
Txns:
| Sold 5,800 shares
@ $40.02, valued at
$232.1k
Sold 1,200 shares
@ $40.02, valued at
$48k
Exercised 1,000 options to buy
@ $3.45, valued at
$3.5k
Exercised 4,800 options to buy
@ $7.5, valued at
$36k
Exercised 1,000 options to buy
@ $3.45, valued at
$3.5k
Exercised 200 options to buy
@ $7.5, valued at
$1.5k
|
|
|
|